Cryptotanshinone Inhibits Cancer Cell Proliferation by Suppressing Mammalian Target of Rapamycin-Mediated Cyclin D1 Expression and Rb Phosphorylation

被引:84
作者
Chen, Wenxing [1 ,4 ]
Luo, Yan [1 ]
Liu, Lei [1 ]
Zhou, Hongyu [1 ]
Xu, Baoshan [1 ]
Han, Xiuzhen [1 ]
Shen, Tao [1 ]
Liu, Zhijun [3 ]
Lu, Yin [4 ]
Huang, Shile [1 ,2 ]
机构
[1] Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA
[2] Louisiana State Univ, Hlth Sci Ctr, Feist Weiller Canc Ctr, Shreveport, LA 71130 USA
[3] Louisiana State Univ, Sch Renewable Nat Resources, Baton Rouge, LA 70803 USA
[4] Nanjing Univ Chinese Med, Nanjing, Jiangsu, Peoples R China
基金
中国国家自然科学基金;
关键词
SALVIA-MILTIORRHIZA BUNGE; BINDING PARTNER; MTOR; PATHWAY; RAPTOR; GROWTH; FEEDBACK; COMPLEX; RICTOR; AKT;
D O I
10.1158/1940-6207.CAPR-10-0020
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cryptotanshinone (CPT), a natural compound isolated from the plant Salvia miltiorrhiza Bunge, is a potential anticancer agent. However, little is known about its anticancer mechanism. Here, we show that CPT inhibited cancer cell proliferation by arresting cells in G(1)-G(0) phase of the cell cycle. This is associated with the inhibition of cyclin D1 expression and retinoblastoma (Rb) protein phosphorylation. Furthermore, we found that CPT inhibited the signaling pathway of the mammalian target of rapamycin (mTOR), a central regulator of cell proliferation. This is evidenced by the findings that CPT inhibited type I insulin-like growth factor 1- or 10% fetal bovine serum-stimulated phosphorylation of mTOR, p70 S6 kinase 1, and eukaryotic initiation factor 4E binding protein 1 in a concentration-and time-dependent manner. Expression of constitutively active mTOR conferred resistance to CPT inhibition of cyclin D1 expression and Rb phosphorylation, as well as cell growth. The results suggest that CPT is a novel antiproliferative agent. Cancer Prev Res; 3(8); 1015-25. (C) 2010 AACR.
引用
收藏
页码:1015 / 1025
页数:11
相关论文
共 56 条
[21]   Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive [J].
Jacinto, E ;
Loewith, R ;
Schmidt, A ;
Lin, S ;
Rüegg, MA ;
Hall, A ;
Hall, MN .
NATURE CELL BIOLOGY, 2004, 6 (11) :1122-U30
[22]   SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity [J].
Jacinto, Estela ;
Facchinetti, Valeria ;
Liu, Dou ;
Soto, Nelyn ;
Wei, Shiniu ;
Jung, Sung Yun ;
Huang, Qiaojia ;
Qin, Jun ;
Su, Bing .
CELL, 2006, 127 (01) :125-137
[23]   Cryptotanshinone inhibits cyclooxygenase-2 enzyme activity but not its expression [J].
Jin, Dao-Zhong ;
Yin, Lin-Lin ;
Ji, Xin-Quan ;
Zhu, Xing-Zu .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2006, 549 (1-3) :166-172
[24]   GβL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR [J].
Kim, DH ;
Sarbassov, DD ;
Ali, SM ;
Latek, RR ;
Guntur, KVP ;
Erdjument-Bromage, H ;
Tempst, P ;
Sabatini, DM .
MOLECULAR CELL, 2003, 11 (04) :895-904
[25]   MTOR interacts with Raptor to form a nutrient-sensitive complex that signals to the cell growth machinery [J].
Kim, DH ;
Sarbassov, DD ;
Ali, SM ;
King, JE ;
Latek, RR ;
Erdjument-Bromage, H ;
Tempst, P ;
Sabatini, DM .
CELL, 2002, 110 (02) :163-175
[26]   Antidiabetes and antiobesity effect of cryptotanshinone via activation of AMP-activated protein kinase [J].
Kim, Eun Ju ;
Jung, Seung-Nam ;
Son, Kun Ho ;
Kim, Sung Ran ;
Ha, Tae Youl ;
Park, Myoung Gyu ;
Jo, In Gun ;
Park, Jong Guk ;
Choe, Wonchae ;
Kim, Sung-Soo ;
Ha, Joohun .
MOLECULAR PHARMACOLOGY, 2007, 72 (01) :62-72
[27]   p53, the cellular gatekeeper for growth and division [J].
Levine, AJ .
CELL, 1997, 88 (03) :323-331
[28]   The decision to enter mitosis: feedback and redundancy in the mitotic entry network [J].
Lindqvist, Arne ;
Rodriguez-Bravo, Veronica ;
Medema, Rene H. .
JOURNAL OF CELL BIOLOGY, 2009, 185 (02) :193-202
[29]   Rapamycin inhibits F-actin reorganization and phosphorylation of focal adhesion proteins [J].
Liu, L. ;
Chen, L. ;
Chung, J. ;
Huang, S. .
ONCOGENE, 2008, 27 (37) :4998-5010
[30]   Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways [J].
Liu, L. ;
Li, F. ;
Cardelli, J. A. ;
Martin, K. A. ;
Blenis, J. ;
Huang, S. .
ONCOGENE, 2006, 25 (53) :7029-7040